<Launch of cephalytic antibiotic Cephacline sustained-release tablets>
In February 2003, the release of Cephaclin extended-release tablets, a second-generation cephalosporin cefaclor drug, began.
Cefaclin extended-release tablets are designed to efficiently absorb cefaclor, which has a narrow absorption area, through the excellent antibacterial activity of existing cefaclor preparations and KyungDong Pharm's formulation technology, improving medication compliance by about 20% with twice-daily administration.
●Ingredient content
Cefaclor 375mg/Tab
●Category number
618/Mainly acts on Gram-positive and Gram-negative bacteria
●Insurance code
A17651641
●Effectiveness and effect
Recurrence of acute bronchitis and chronic bronchitis: S.pneumoniae, H. influenzae (including beta-lactamase-producing strains), H.parainfluenzae, M.catarrhalis (including beta-lactamase-producing strains), and S.aureus
Pharyngitis and tonsillitis: S.pyrogenes (Group A beta-hemolytic streptococcus)
Simple infections of the lower urinary tract (including cystitis and asymptomatic bacteriuria): E.coli, K.pneumoniae, and S. saprophyticus
Skin and soft tissue infections: S.pyogenes (group A beta-hemolytic streptococcus), S. aureus (including beta-lactamase producing strains), S. epidermidis (including beta-lactamase producing strains)
<Indications>
Otitis media, pneumonia, pharyngitis, tonsillitis, bronchitis, pyelonephritis, cystitis, gonococcal urethritis, swelling, carbuncle, folliculitis, cellulitis, infectious atheroma, subcutaneous abscess, epidermis, wound infection
●Usage dosage
Pharyngitis, migraine, skin and soft tissue infections: twice a day, 375 mg once
Lower urinary tract infection: 375mg twice a day or 500mg once a day
Bronchitis: 2 times a day, 375mg once or 2 times a day, 500mg once
In the treatment of infections caused by S.pyogenes (group A streptococci), this drug must be administered continuously for more than 10 days.
●Standard drug price
1115 won
●Packing unit
100T